PMS23 Cost Per Treated Rheumatoid Arthritis (RA) Patient for Etanercept, Adalimumab and Infliximab: A Retrospective Claims Database Analysis

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.03.212
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Etanercept May Induce Neurosarcoidosis in a Patient Treated for Rheumatoid Arthritis

BMC Neurology
MedicineNeurology
2013English

Cost Per Responder of Apremilast Versus Etanercept and Adalimumab in Patients With Active Psoriatic Arthritis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Rheumatoid Arthritis-Associated Uveitis Treated With Adalimumab

Klinika Oczna
MedicineOphthalmology
2019English

Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis

Journal of Managed Care Pharmacy
2006English

SAT0117 Retention Rates of Adalimumab, Etanercept, and Infliximab as 1st- Or 2nd-Line Biotherapy for Rheumatoid Arthritis Patients in Daily Practice in Auvergne

2017English

Cost-Utility Analysis of Infliximab and Adalimumab for Refractory Ulcerative Colitis

Cost Effectiveness and Resource Allocation
Health Policy
2009English

Fatal Pulmonary Mycobacterium Xenopi in a Patient With Rheumatoid Arthritis Receiving Etanercept

Thorax
PulmonaryRespiratory Medicine
2007English

Comparison of the Efficacy of the Tumour Necrosis Factor Blocking Agents Adalimumab, Etanercept, and Infliximab When Added to Methotrexate in Patients With Active Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy